ODS for PRR is a given, it is just when it is announced and the trial start ann., etc.
It is an error to think there is some mystery to why PRR is being re-rated, and that re-rating is not finished.
We can observe that successful shift to phase III trials provides a tremendous kick for the SP and so design of the PRR phase II trial for rapid segue into phase III is a good thing.
Zeltia's Yondelis phase II trial findings, presented at the European Society for Medical Oncology conference in Edinburgh, showed that out of 36 patients evaluated, there was one partial objective response among the 19 refractory patients, and 8 responses (1 complete and 7 partial) in 17 relapsed patients.
orphan drug status, page-2
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.020(6.67%) |
Mkt cap ! $464.8M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 32.3¢ | 30.0¢ | $1.040M | 3.328M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 42705 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |